Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds [Biochemistry]

The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein–protein interactions. We have refined crystallization conditions for KRAS169Q61H-yielding crystals suitable for soaking with compounds and exploited this to...

http://bit.ly/2St2yLa